Overview

A Study Comparing User Experience of Different Delivery Devices for Glucagon

Status:
Completed
Trial end date:
2019-01-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Glucagon
Glucagon-Like Peptide 1